Akero Therapeutics
97 articles with Akero Therapeutics
-
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
3/17/2023
Akero Therapeutics, Inc. today reported fourth quarter and full year financial results for the period ending December 31, 2022.
-
Industry leaders say the second generation of interventions for nonalcoholic steatohepatitis is likely to succeed where first-generation approaches stumbled.
-
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
1/10/2023
Akero Therapeutics, Inc. today announced the appointment of Patrick Lamy as Senior Vice President, Commercial Strategy.
-
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 10:30 a.m. P.T. in San Francisco, CA.
-
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
12/21/2022
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b SYMMETRY main study evaluating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH), in patients with compensated cirrhosis fibrosis stage 4 (F4).
-
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASHDesignation based on Akero’s Phase 2b HARMONY study
12/8/2022
Akero Therapeutics, Inc. has received a Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of nonalcoholic steatohepatitis (NASH).
-
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November 2022
11/10/2022
Akero Therapeutics, Inc. announced that management will present at the following investor conferences this month:
-
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category
11/7/2022
Akero Therapeutics, Inc. announced it will present late-breaking oral and poster presentations on its lead product candidate efruxifermin (EFX) today at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting 2022 being held in Washington, D.C.
-
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/4/2022
Akero Therapeutics, Inc. today reported third quarter financial results for the period ending September 30, 2022 and provided business updates.
-
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
10/11/2022
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.
-
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - September 15, 2022
9/15/2022
Akero Therapeutics, Inc. announced the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share.
-
Oramed announced positive mid-stage data that showed its investigational drug ORMD-0801 reduced liver fat content in type 2 diabetes patients who have been diagnosed with NASH.
-
In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks
9/13/2022
Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic nonalcoholic steatohepatitis, fibrosis stage 2 or 3.
-
Akero Therapeutics Announces Proposed Public Offering of Common Stock - September 13, 2022
9/13/2022
Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced that it has commenced an underwritten public offering of $175.0 million of shares of its common stock.
-
Akero Therapeutics announced its mid-stage drug candidate, efruxifermin improved liver fibrosis and prevented disease worsening in patients with NASH.
-
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASHInvestor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data
9/8/2022
Akero Therapeutics, Inc. (Nasdaq: AKRO), will hold an investor conference on Tuesday, September 13 at 8:00 a.m. ET to share results from its HARMONY study, a double-blind, placebo-controlled Phase 2b study evaluating the efficacy of efruxifermin (EFX) in patients with pre-cirrhotic non-alcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3).
-
Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment
8/24/2022
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis (NASH) have been published in JHEP Reports.
-
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, reported second quarter financial results for the period ending June 30, 2022 and provided business updates.
-
Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology
6/27/2022
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation of an analysis from its Phase 2a BALANCED study of efruxifermin (EFX) in patients with biopsy-confirmed F1-F3 fibrosis associated with non-alcoholic steatohepatitis (NASH).
-
Shares of Akero Therapeutics are surging after the company announced pharma giant Pfizer made a $25 million equity investment to support the development of the company’s experimental liver drug.